NCT03213080View on ClinicalTrials.gov

Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

December 31, 2017

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
COPD
Interventions
DEVICE

Targeted Lung Denervation (TLD)

Targeted Lung Denervation (TLD) procedure.

Sponsors

Lead Sponsor

Nuvaira, Inc.
All Listed Sponsors
lead

Nuvaira, Inc.

INDUSTRY

NCT03213080 - Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population | Biotech Hunter | Biotech Hunter